Floatz logo

Therapeutic Asset Ratings

435 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Olanzapine
Colorectal Cancer
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Breast Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Sarcoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Ovarian Cancer
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Malignant Pancreatic Neoplasm
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Prostate Cancer
OHSU Knight Cancer InstituteP2CCC (53)
Oxodotreotide
Breast Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Palbociclib
Plasma Cell Myeloma
OHSU Knight Cancer InstituteP2CCC (53)
Palbociclib
Prostate Cancer
OHSU Knight Cancer InstituteP2CCC (53)
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937
Pancreatic Adenocarcinoma
OHSU Knight Cancer InstituteP2CCC (53)
TAMOXIFEN
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP2CCC (53)
TAMOXIFEN
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
TAMOXIFEN
Malignant Pancreatic Neoplasm
OHSU Knight Cancer InstituteP2CCC (53)
TRASTUZUMAB
Plasma Cell Myeloma
OHSU Knight Cancer InstituteP2CCC (53)
Trastuzumab Emtansine
Ovarian Cancer
OHSU Knight Cancer InstituteP2CCC (53)
Xeomin®
Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Eribulin
Sarcoma
OHSU Knight Cancer InstituteP1CCC (53)
Palbociclib
Sarcoma
OHSU Knight Cancer InstituteP1CCC (53)
(+)-VINCRISTINE
Advanced Pancreatic Carcinoma
OHSU Knight Cancer InstituteP1CCC (53)
Cobimetinib
Ovarian Cancer
OHSU Knight Cancer InstituteP2CCC (52)
Eribulin
Ovarian Carcinoma
OHSU Knight Cancer InstituteP1CCC (52)
Showing 251 to 275 of 435 assets
PreviousPage 11 of 18Next